Shares Of Enzo Life Sciences Spike Higher After Co. Gets FDA Emergency Use Authorization For Its AMPIPROBE Coronavirus Test System
Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.
The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product."
www.fda.gov/media/139829/download
seekingalpha.com/new...s-covidminus-19-test
Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.
The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product."
www.fda.gov/media/139829/download
seekingalpha.com/new...s-covidminus-19-test